Print this
Alternatively, continue daily injection at a reduced dose of 0.5 to 1mg
A clear demonstration was obtained that BPC 157 stimulated both the egr-1 gene (critical in proliferation, differentiation, and inflammation during cholestatic liver injury, cytokine and growth factor generation, and early extracellular matrix (collagen) formation) (Zhang et al., 2011) and its co-repressor gene nab2 (Seveljevic-Jaran et al., 2006
It triggers production of antioxidant response elements and intermediates that work to regulate energy homeostatis.1 In vitro data suggests MOTs-C interacts with a variety of pathways, including activating the JAK pathway (impact on aging), inhibiting mTOR signaling (immune and aging impact), inhibition of STAT3 (improved muscle function), activation of ERK pathway (obesity prevention), and translocation of GLUT4 (reduced insulin resistance).2,3 In response to this in vitro data, animal studies to determine actual biological impact have evaluated the impact of exogenous MOTs-C on the body
WHO SHOULD TAKE LIPOSOMAL BPC: Liposomal BPC is ideal for individuals with acute reparative needs: Those recovering from injury, surgery, or physical overexertion, those looking to support tissue healing and repair, vascular health, and neurological resilience
It suppresses the TGF-/Smad pathway, reducing the expression of ECM-related genes like collagen I and III [148]